Key result
Treg-specific deletion of amphiregulin reduced allograft fibrosis and vasculopathy, demonstrating that IL-33-induced Treg repair responses paradoxically contribute to chronic rejection.
Why the study?
Chronic rejection after organ transplantation causes immunosuppression-resistant vascular remodeling and fibrosis, but the underlying repair mechanisms remain incompletely understood.
Does Treg-derived amphiregulin contribute to chronic rejection and fibrosis in heart transplantation?
Does Treg-derived amphiregulin contribute to chronic rejection and fibrosis in heart transplantation?
Treg-secreted amphiregulin, driven by graft IL-33, paradoxically promotes fibroblast proliferation and contributes to chronic rejection and allograft vasculopathy after heart transplantation.
Answers are grounded in this paper and cite their sources.
Treg Areg promotes murine cardiac allograft fibrosis; hypothesis-generating for Areg targeting to limit chronic rejection in humans.
Chronic rejection (CR) after organ transplantation is alloimmune injury manifested by graft vascular remodeling and fibrosis that is resistant to immunosuppression. Single-cell RNA-Seq analysis of MHC class II-mismatched (MHCII-mismatched) heart transplants developing chronic rejection identified graft IL-33 as a stimulator of tissue repair pathways in infiltrating macrophages and Tregs. Using IL-33-deficient donor mice, we show that graft fibroblast-derived IL-33 potently induced amphiregulin (Areg) expression by recipient Tregs. The assessment of clinical samples also confirmed increased expression of Areg by intragraft Tregs also during rejection. Areg is an EGF secreted by multiple immune cells to shape immunomodulation and tissue repair. In particular, Areg is proposed to play a major role in Treg-mediated muscle, epithelium, and nerve repair. Assessment of recipient mice with Treg-specific deletion of Areg surprisingly uncovered that Treg secretion of Areg contributed to CR. Specifically, heart transplants from recipients with Areg-deficient Tregs showed less fibrosis, vasculopathy, and vessel-associated fibrotic niches populated by recipient T cells. Mechanistically, we show that Treg-secreted Areg functioned to increase fibroblast proliferation. In total, these studies identify how a dysregulated repair response involving interactions between IL-33+ fibroblasts in the allograft and recipient Tregs contributed to the progression of CR.
No takes yet. Share an insight, caveat, or question.
Warunek et al. (2024) studied Chronic rejection after heart transplantation. Treg-specific deletion of Amphiregulin (Areg) vs. Areg-competent Tregs (Foxp3 YFP-Cre) was evaluated on Allograft fibrosis and vasculopathy. Treg-specific deletion of amphiregulin reduced allograft fibrosis and vasculopathy, demonstrating that IL-33-induced Treg repair responses paradoxically contribute to chronic rejection.
Synapse has enriched 10 related papers. Consider them for comparative context: